EW · 10-Q · 2026Q2 · Full report

Operating Cash Flow and Capex

Edwards Lifesciences Corp · 2026-08-04 · Importance 59 · Surprise 48

Operating cash flow increased $125.1 million year over year to $695.7 million for the six months ended June 30, 2026. The improvement primarily reflected lower tax payments, while higher working-capital needs partially offset the benefit. Investing cash outflows were $286.0 million and included $131.8 million of capital expenditures, $53.2 million of notes receivable issuance, and $33.7 million of net business-combination payments. Capital expenditures increased from $105.3 million in the first six months of 2025 to $131.8 million in 2026.

Key facts

• Net cash flows provided by operating activities were $695.7 million for the six months ended June 30, 2026, an increase of $125.1 million over the same period last year primarily due to lower tax payments. source
• Net cash used in investing activities was $286.0 million for the six months ended June 30, 2026, consisting primarily of capital expenditures of $131.8 million, issuance of notes receivable of $53.2 million, and net payments of $33.7 million related to business combinations, partially offset by net purchases of investments of $63.0 million. source
• Net cash used in investing activities for the six months ended June 30, 2025 was $86.8 million and consisted primarily of capital expenditures of $105.3 million, issuance of notes receivable of $70.6 million, a $36.3 million payment for a working capital adjustment related to the sale of Critical Care, and $17.0 million payment of acquisition options, partially offset by net proceeds from investments of $145.8 million. source